<?xml version="1.0" encoding="UTF-8"?>

<Bundle xmlns="http://hl7.org/fhir">
  <id value="bundlepackageleaflet-talzenna01-025-1" />
  <meta>
    <versionId value="TE 6_1"/>
    <lastUpdated value="2024-04-11T00:00:00Z" />
    <profile
      value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi" />
  </meta>
  <language value="en" />
  <identifier>
    <system value="https://www.mhra.gov.uk/" />
    <value value="talzenna" />
  </identifier>
  <type value="document" />
  <timestamp value="2024-04-11T00:00:00Z" />
  <entry>
    <fullUrl value="Composition/compositionuken" />
    <resource>
      <Composition>
        <id value="compositionuken" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi" />
        </meta>
        <language value="en"/>
        <version value="TE 6_1"/>
        <contained>
          <Binary>
              <id value="ibrance01" />
              <contentType value="image/jpg" />
              <data
                  value="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" />
          </Binary>
        </contained>
        <identifier>
          <system value="https://www.mhra.gov.uk/" />
          <value value="0d69fdcb-33cf-407f-8209-a6529856ab4f" />
        </identifier>
        <status value="final" />
        <type>
          <coding>
            <system value="https://www.mhra.gov.uk/" />
            <code value="100000155538" />
          </coding>
          <text value="Package Leaflet" />
        </type>
        <subject>
          <reference value="MedicinalProductDefinition/mp01mg" />
        </subject>
        <subject>
          <reference value="MedicinalProductDefinition/mp1mg" />
        </subject>
        <subject>
          <reference value="MedicinalProductDefinition/mp025mg" />
        </subject>
        <date value="2024-04-11T00:00:00Z" />
        <author>
          <reference value="Organization/orgpfizerukltd" />
        </author>
        <title centered="true" value="Talzenna® (talazoparib) 0.1 mg, 0.25 mg and 1 mg hard capsules" />
        <section>
          <title centered="true" value="Package leaflet: Information for the patient" />
          <code>
            <coding>
              <system value="https://www.mhra.gov.uk/" />
              <code value="200000029894" />
            </coding>
            <text value="Package leaflet: Information for the patient" />
          </code>
          <text>
            <status value="generated" />
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p style="text-align: center;" class="mg-01">
                <b>Talzenna<sup>&#174;</sup> 0.1 mg hard capsules</b>
              </p>
              <p style="text-align: center;" class="mg-025">
                <b>Talzenna<sup>&#174;</sup> 0.25 mg hard capsules</b>
              </p>
              <p style="text-align: center;" class="mg-1">
                <b>Talzenna<sup>&#174;</sup> 1 mg hard capsules</b>
              </p>
              <p style="text-align: center;">talazoparib</p>
              <p>&#9660; This medicine is subject to additional monitoring. This will allow quick
                identification of new safety information. You can help by reporting any side effects
                you may get. See the end of section 4 for how to report side effects.</p>
              <p>
                <b>Read all of this leaflet carefully before you start taking this medicine because
                  it contains important information for you.</b>
              </p>
              <ul>
                <li>Keep this leaflet. You may need to read it again.</li>
                <li>If you have any further questions, ask your doctor, pharmacist or nurse.</li>
                <li>This medicine has been prescribed for you only. Do not pass it on to others. It
                  may harm them, even if their signs of illness are the same as yours.</li>
                <li>If you get any side effects, talk to your doctor, pharmacist or nurse. This
                  includes any possible side effects not listed in this leaflet. See <a href="#7a996bcf-6f26-4e0e-ba8b-cb1c23c286b8">section 4</a>.</li>
              </ul>
              <img src="#ibrance01" alt="Chemical Structure of Palbociclib for testing purposes" />
            </div>
          </text>
          <section>
            <title value="What is in this leaflet" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="100000155538" />
              </coding>
              <text value="What is in this leaflet" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <ol>
                  <li><a href="#5a34d358-e830-4308-8d86-cb1dc8b1ee8c">What Talzenna is and what it is used for</a></li>
                  <li><a href="#a2f089b4-fef4-497e-81bd-251cd9c7571f">What you need to know before you take Talzenna</a></li>
                  <li><a href="#958ed385-b409-41d8-a868-fa5ec1fbaba4">How to take Talzenna</a></li>
                  <li><a href="#7a996bcf-6f26-4e0e-ba8b-cb1c23c286b8">Possible side effects</a></li>
                  <li><a href="#eb80ccf5-f971-4361-b25c-b8d86c457a00">How to store Talzenna</a></li>
                  <li><a href="#2531776f-f478-40bc-a19d-6970524b8793">Contents of the pack and other information</a></li>
                </ol>
              </div>
            </text>
          </section>
        </section>
        <section id="5a34d358-e830-4308-8d86-cb1dc8b1ee8c">
          <title value="1. What Talzenna is and what it is used for" />
          <code>
            <coding>
              <system value="https://www.mhra.gov.uk/" />
              <code value="200000029895" />
            </coding>
            <text value="1. What X is and what it is used for" />
          </code>
          <text>
            <status value="generated" />
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>
                <b>What Talzenna is and how it works</b>
              </p>
              <p>Talzenna contains the active substance talazoparib. It is a type of anticancer
                medicine known as a ‘PARP (poly-ADP ribose polymerase) inhibitor’.</p>
              <p>Talzenna works by blocking PARP, which is an enzyme that
                repairs damaged DNA in certain cancer cells. As a result, the cancer cells can no
                longer repair themselves and they die.</p>
              <p>
                <b>What Talzenna is used for</b>
              </p>
              <p>Talzenna is a medicine used </p>
              <ul>
                <li><p class="breastCancer">alone to treat adults with breast cancer of a type
                known as HER2-negative breast cancer who have an abnormal inherited BRCA gene. Your healthcare provider will perform a test to make sure that Talzenna is right for you. </p></li>
                <li><p class="prostateCancer">in combination with a medicine called enzalutamide, to treat adults with prostate cancer who no longer respond to a hormone therapy or surgical treatment to lower testosterone.</p> </li>
              </ul>              
              <p>Talzenna is used when the cancer has spread beyond the original tumour or to other
                parts of the body.</p>
              <p>If you have any questions about how Talzenna works or why this medicine has been
                prescribed for you, ask your doctor.</p>
            </div>
          </text>
        </section>
        <section id="a2f089b4-fef4-497e-81bd-251cd9c7571f">
          <title value="2. What you need to know before you take Talzenna" />
          <code>
            <coding>
              <system value="https://www.mhra.gov.uk/" />
              <code value="200000029896" />
            </coding>
            <text value="2. What you need to know before you take X" />
          </code>
          <section>
            <title cssClass="doNotTakeTanzenna" value="Do not take Talzenna" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029897" />
              </coding>
              <text value="Do not &amp;lt;take&amp;gt;; &amp;lt;use&amp;gt; X" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <ul>
                  <li class="allergen">
                    <p>If you are allergic to talazoparib or any of the other ingredients of this
                      medicine (listed in section 6).</p>
                  </li>
                  <li class="breastFeeding">
                    <p>If you are breast-feeding.</p>
                  </li>
                </ul>
              </div>
            </text>
          </section>
          <section>
            <title value="Warnings and precautions" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029898" />
              </coding>
              <text value="Warnings and precautions" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>Talk to your doctor, pharmacist or nurse before taking Talzenna and during your
                  treatment if you experience signs or symptoms described in this section.</p>
                <p>
                  <u>Low blood cell counts</u>
                </p>
                <p>Talzenna lowers your blood cell counts, such as your red blood cell count
                  (anaemia), white blood cell count (neutropenia), or blood platelet count
                  (thrombocytopenia). Signs and symptoms you need to look out for include:</p>
                <ul>
                  <li>
                    <p><b>Anaemia: </b>Being short of breath, feeling very tired, pale skin, or fast
                      heartbeat – these may be signs of a low red blood cell count.</p>
                  </li>
                  <li>
                    <p><b>Neutropenia: </b>Infection, developing chills or shivering, or fever –
                      these may be signs of a low white blood cell count.</p>
                  </li>
                  <li>
                    <p><b>Thrombocytopenia: </b>Bruising or bleeding for longer than usual if you
                      hurt yourself – these may be signs of a low blood platelet count.</p>
                  </li>
                </ul>
                <p>You will have regular blood tests during treatment with Talzenna to check your
                  blood cells (white blood cells, red blood cells, and platelets).</p>
                <p>
                  <u>Serious problems with the bone marrow</u>
                </p>
                <p>Rarely, low blood cell counts may be a sign of more serious problems with the
                  bone marrow such as myelodysplastic syndrome (MDS) or acute myeloid leukaemia
                  (AML). Your doctor may want to test your bone marrow to check for these problems.</p>
                <p><u>Blood clots</u></p>
                <p>Talzenna may cause blood clots in the veins. Tell your doctor, pharmacist or nurse if you experience signs or symptoms of blood clots in the veins such as pain or stiffness, swelling and redness in the affected leg (or arm), chest pain, shortness of breath or lightheadedness.</p>
                <p>
                  <u>Male and female contraception</u>
                </p>
                <p class="Adolescent Adult Elderly">Women who can become pregnant and men with
                  partners who are or can become pregnant should use effective contraception.</p>
                <p class="Adolescent Adult Elderly">Please see section <a href="#698cd895-3954-4de6-80f1-f65fcc40288f">“Male and female
                  contraception”</a> below.</p>
              </div>
            </text>
          </section>
          <section>
            <title cssClass="Under18" value="Children and adolescents" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029899" />
              </coding>
              <text value="Children and adolescents" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml" class="Under18">
                <p>Talzenna is not to be used in children or adolescents (under 18 years of age).</p>
              </div>
            </text>
          </section>
          <section>
            <title value="Other medicines and Talzenna" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029900" />
              </coding>
              <text value="Other medicines and Talzenna" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or
                  might take any other medicines. This includes medicines obtained without a
                  prescription and herbal medicines. This is because Talzenna can affect the way
                  some other medicines work. Also some medicines can affect the way Talzenna works.</p>
                <p
                  class="Amiodarone carvedilol dronedarone propafenone quinidine ranolazine verapamil Clarithromycin erythromycin Itraconazole ketoconazole Cobicistat darunavir indinavir lopinavir ritonavir saquinavir telaprevir tipranavir Ciclosporin Curcumin turmericRoot">In
                  particular, the following may increase the risk of side effects with Talzenna:</p>
                <ul>
                  <li
                    class="Amiodarone carvedilol dronedarone propafenone quinidine ranolazine verapamil">
                    <p>Amiodarone, carvedilol, dronedarone, propafenone, quinidine, ranolazine and
                      verapamil – generally used to treat heart problems.</p>
                  </li>
                  <li class="Clarithromycin erythromycin">
                    <p>Clarithromycin and erythromycin antibiotics – used to treat bacterial
                      infections.</p>
                  </li>
                  <li class="Itraconazole ketoconazole">
                    <p>Itraconazole and ketoconazole – used to treat fungal infections.</p>
                  </li>
                  <li
                    class="Cobicistat darunavir indinavir lopinavir ritonavir saquinavir telaprevir tipranavir">
                    <p>Cobicistat, darunavir, indinavir, lopinavir, ritonavir, saquinavir,
                      telaprevir and tipranavir used to treat HIV infections/AIDS.</p>
                  </li>
                  <li class="Ciclosporin">
                    <p>Ciclosporin – used in organ transplantation to prevent rejection.</p>
                  </li>
                  <li class="Lapatinib">
                    <p>Lapatinib – used to treat patients with certain types of breast cancer.</p>
                  </li>
                  <li class="Curcumin turmericRoot">
                    <p>Curcumin (e.g. found in turmeric root) in some medicines (see also section
                      Talzenna with food and drink below).</p>
                  </li>
                </ul>
                <p class="Carbamazepine phenytoin StJohnsWort">The following medicines may reduce
                  the effect of Talzenna:</p>
                <ul>
                  <li class="Carbamazepine phenytoin">
                    <p>Carbamazepine and phenytoin – anti-epileptics used to treat seizures or fits.</p>
                  </li>
                  <li class="StJohnsWort">
                    <p>St. John’s wort (<i>Hypericum perforatum</i>) – a herbal remedy used to treat
                      mild depression and anxiety.</p>
                  </li>
                </ul>
              </div>
            </text>
          </section>
          <section>
            <title value="Talzenna with food and drink" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029901" />
              </coding>
              <text
                value="X with &amp;lt;food&amp;gt; &amp;lt;and&amp;gt; &amp;lt;,&amp;gt; &amp;lt;drink&amp;gt; &amp;lt;and&amp;gt; &amp;lt;alcohol&amp;gt;" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>Do not use curcumin in food supplements while you are taking Talzenna as it may
                  increase Talzenna’s side effects. Curcumin is found in turmeric root and you
                  should not use large amounts of turmeric root, but using spices in food is not
                  likely to cause a problem.</p>
              </div>
            </text>
          </section>
          <section>
            <title value="Pregnancy" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029902" />
              </coding>
              <text
                value="Pregnancy &amp;lt;and&amp;gt; &amp;lt;,&amp;gt; breast-feeding &amp;lt;and fertility&amp;gt;" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>Talzenna could harm an unborn baby. <span class="Female">If you are pregnant or
                  breast-feeding, think you may be pregnant or are planning to have a baby, ask your
                  doctor or pharmacist for advice before taking this medicine. Your doctor will
                  perform a pregnancy test prior to starting Talzenna.</span></p>
                <ul>
                  <li class="Pregnant">
                    <p>You should not use Talzenna if you are pregnant.</p>
                  </li>
                  <li class="Female">
                    <p>You should not become pregnant while taking Talzenna.</p>
                  </li>
                  <li>
                    <p>Discuss contraception with your doctor if there is any possibility that you
                      or your partner may become pregnant.</p>
                  </li>
                </ul>
                <p id="698cd895-3954-4de6-80f1-f65fcc40288f">
                  <b>Male and female contraception</b>
                </p>
                <p class="Female"><b>Women </b>who are able to become pregnant should use effective
                  birth control (contraception) during treatment with Talzenna and for at least 7
                  months after the last dose of Talzenna. Since the use of hormonal contraception is
                  not recommended if you have breast cancer, you should use two non-hormonal
                  contraception methods.</p>
                <p class="Female">Talk to your healthcare provider about birth control methods that
                  may be right for you.</p>
                <p class="Male"><b>Men </b>with female partners who are pregnant or able to become
                  pregnant should use effective birth control (contraception), even after a
                  vasectomy, during treatment with Talzenna and for at least 4 months after the last
                  dose.</p>
              </div>
            </text>
          </section>
          <section>
            <title cssClass="breastFeeding" value="Breast-feeding" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029902" />
              </coding>
              <text value="Breast-feeding" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p class="breastFeeding">You should not breast-feed while taking Talzenna and for at
                  least 1 month after the last dose. It is not known if Talzenna passes into breast
                  milk.</p>
              </div>
            </text>
          </section>
          <section>
            <title cssClass="Male" value="Fertility" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029902" />
              </coding>
              <text value="Fertility" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p class="Male">Talazoparib may reduce fertility in men.</p>
              </div>
            </text>
          </section>
          <section>
            <title value="Driving and using machines" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029903" />
              </coding>
              <text value="Driving and using machines" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>Talzenna may have a minor influence on the ability to drive and use machines. If
                  you feel dizzy, weak, or tired (these are very common side effects of Talzenna),
                  you should not drive or use machines.</p>
              </div>
            </text>
          </section>
        </section>
        <section id="958ed385-b409-41d8-a868-fa5ec1fbaba4">
          <title value="3. How to take Talzenna" />
          <code>
            <coding>
              <system value="https://www.mhra.gov.uk/" />
              <code value="200000029905" />
            </coding>
            <text value="3. How to &amp;lt;take&amp;gt; &amp;lt;use&amp;gt; X" />
          </code>
          <text>
            <status value="generated" />
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check
                with your doctor or pharmacist if you are not sure.</p>
              <p>
                <b>How much to take</b>
              </p>
              <p>Talzenna is taken by mouth once daily. The recommended dose is:</p>
              <ul>
                <li><p class="breastCancer">for breast cancer: one 1 mg capsule of Talzenna.</p></li>
                <li><p class="prostateCancer">for prostate cancer: Talzenna is taken with a medicine called enzalutamide. The usual dose of Talzenna is 0.5 mg (two 0.25 mg capsules).</p></li>
              </ul>                
              <p>If you get certain side effects while you are taking Talzenna alone or in combination with enzalutamide (see <a href="#7a996bcf-6f26-4e0e-ba8b-cb1c23c286b8">section 4</a>), your doctor may lower your dose or stop treatment, either temporarily or permanently. Take Talzenna and enzalutamide exactly as your doctor has told you. </p>
              <p>Swallow the capsule whole with a glass of water. Do not chew or crush the capsules. You can take Talzenna with food or between meals. Do not open the capsules. Contact with the capsule content should be avoided.</p>
            </div>
          </text>
          <section>
            <title value="If you take more Talzenna than you should" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029907" />
              </coding>
              <text value="If you &amp;lt;take&amp;gt; &amp;lt;use&amp;gt; more X than you should" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>If you have taken more Talzenna than your normal dose, contact your doctor or
                  nearest hospital right away. Urgent treatment may be necessary.</p>
                <p>Take the carton and this leaflet so that the doctor knows what you have been
                  taking.</p>
              </div>
            </text>
          </section>
          <section>
            <title value="If you forget to take Talzenna" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029908" />
              </coding>
              <text value="If you forget to &amp;lt;take&amp;gt; &amp;lt;use&amp;gt; X" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>If you miss a dose or vomit, take your next dose as scheduled. Do not take a
                  double dose to make up for the forgotten or vomited capsules.</p>
              </div>
            </text>
          </section>
          <section>
            <title value="If you stop taking Talzenna" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029909" />
              </coding>
              <text value="If you stop &amp;lt;taking&amp;gt; &amp;lt;using&amp;gt; X" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>Do not stop taking Talzenna unless your doctor tells you to.</p>
                <p>If you have any further questions on the use of this medicine, ask your doctor or
                  pharmacist or nurse.</p>
              </div>
            </text>
          </section>
        </section>
        <section id="7a996bcf-6f26-4e0e-ba8b-cb1c23c286b8">
          <title value="4. Possible side effects" />
          <code>
            <coding>
              <system value="https://www.mhra.gov.uk/" />
              <code value="200000029910" />
            </coding>
            <text value="4. Possible side effects" />
          </code>
          <text>
            <status value="generated" />
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>Like all medicines, this medicine can cause side effects, although not everybody
                gets them.</p>
              <p>
                <b>Tell your doctor straight away if you notice any of the following symptoms which
                  could be a sign of serious blood disorder:</b>
              </p>
              <p><b>Very common</b> (may affect more than 1 in 10 people)</p>
              <ul>
                <li>Being short of breath, feeling very tired, having pale skin, or fast heartbeat –
                  these may be signs of a low red blood cell count (anaemia).</li>
                <li>Infection, developing chills or shivering, or fever or feeling hot – these may
                  be signs of a low white blood cell count (neutropenia).</li>
                <li>Bruising or bleeding for longer than usual if you hurt yourself – these may be
                  signs of a low blood platelet count (thrombocytopenia).</li>
              </ul>
              <p>
                <b>Talk to your doctor if you get any other side effects. These can include:</b>
              </p>
              <p><b>Very common</b> (may affect more than 1 in 10 people)</p>
              <ul>
                <li>Low counts of white blood cells, red blood cells, and blood platelets</li>
                <li>Decreased appetite</li>
                <li>Feeling dizzy</li>
                <li>Headache</li>
                <li>Feeling sick (nausea)</li>
                <li>Being sick (vomiting)</li>
                <li>Diarrhoea</li>
                <li>Pain in the abdomen</li>
                <li>Hair loss</li>
              </ul>
              <p><b>Common</b> (may affect up to 1 in 10 people)</p>
              <ul>
                <li>Alteration in taste (dysgeusia)</li>
                <li>Painful swollen leg, chest pain, shortness of breath, rapid breathing or rapid heart rate as these can be signs of blood clots in the vein</li>
                <li>Indigestion</li>
                <li>Mouth inflammation</li>
              </ul>
              <p><b>Uncommon</b> (may affect up to 1 in 100 people)</p>
              <ul>
                <li>Abnormal blood cell counts due to serious problems with bone marrow (myelodysplastic syndrome or acute myeloid leukaemia). See Warnings and precautions in <a href="#a2f089b4-fef4-497e-81bd-251cd9c7571f">Section 2</a></li>
              </ul>
            </div>
          </text>
          <section>
            <title value="Reporting of side effects" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029912" />
              </coding>
              <text value="Reporting of side effects" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>If you get any side effects, talk to your doctor, pharmacist or nurse. This
                  includes any possible side effects not listed in this leaflet. You can also report
                  side effects directly via the Yellow Card Scheme at: <a
                    href="https://www.mhra.gov.uk/yellowcard">www.mhra.gov.uk/yellowcard</a> or
                  search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting
                  side effects you can help provide more information on the safety of this medicine.</p>
              </div>
            </text>
          </section>
        </section>
        <section id="eb80ccf5-f971-4361-b25c-b8d86c457a00">
          <title value="5. How to store Talzenna" />
          <code>
            <coding>
              <system value="https://www.mhra.gov.uk/" />
              <code value="200000029913" />
            </coding>
            <text value="5. How to store X" />
          </code>
          <text>
            <status value="generated" />
            <div xmlns="http://www.w3.org/1999/xhtml">
              <p>Keep this medicine out of the sight and reach of children.</p>
              <p>Do not use this medicine after the expiry date which is stated on the carton and
                the bottle or blister after EXP. The expiry date refers to the last day of that
                month.</p>
              <p>This medicine does not require any special storage conditions.</p>
              <p>Do not use this medicine if the pack is damaged or shows signs of tampering.</p>
              <p>Do not throw away any medicines via wastewater or household waste. Ask your
                pharmacist how to throw away medicines you no longer use. These measures will help
                protect the environment.</p>
            </div>
          </text>
        </section>
        <section id="2531776f-f478-40bc-a19d-6970524b8793">
          <title value="6. Contents of the pack and other information" />
          <code>
            <coding>
              <system value="https://www.mhra.gov.uk/" />
              <code value="200000029914" />
            </coding>
            <text value="6. Contents of the pack and other information" />
          </code>
          <section>
            <title value="What Talzenna contains" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029915	" />
              </coding>
              <text value="What X contains" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>The active substance is talazoparib. Talzenna hard capsules come in different
                  strengths.</p>
                <ul>                  
                  <li class="mg-01">Talzenna 0.1 mg hard capsules: each capsule contains talazoparib tosylate equivalent to 0.1 mg talazoparib.</li>
                  <li class="mg-025">
                    <p>Talzenna 0.25 mg hard capsules: each capsule contains talazoparib tosylate
                      equivalent to 0.25 mg talazoparib.</p>
                  </li>
                  <li class="mg-1">
                    <p>Talzenna 1 mg hard capsules: each capsule contains talazoparib tosylate
                      equivalent to 1 mg talazoparib.</p>
                  </li>
                </ul>
                <p>The other ingredients are:</p>
                <ul>
                  <li>
                    <p>Capsule content: silicified microcrystalline cellulose (microcrystalline cellulose and silicone dioxide).</p>
                  </li>
                  <li class="mg-01">0.1 mg capsule shell: hypromellose and titanium dioxide (E171).</li>
                  <li class="mg-025">
                    <p>0.25 mg capsule shell: hypromellose, yellow iron oxide (E172), and
                      titanium dioxide (E171)</p>
                  </li>
                  <li class="mg-1">
                    <p>1 mg capsule shell: hypromellose, yellow iron oxide (E172), titanium
                      dioxide (E171), and red iron oxide (E172)</p>
                  </li>
                </ul>
                <p>Printing ink: shellac (E904), propylene glycol (E1520), ammonium hydroxide
                  (E527), black iron oxide (E172), and potassium hydroxide (E525).</p>
              </div>
            </text>
          </section>
          <section>
            <title value="What Talzenna looks like and contents of the pack" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029916" />
              </coding>
              <text value="What X looks like and contents of the pack" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p class="mg-01">	Talzenna 0.1 mg is supplied as opaque, approximately 14 mm x 5 mm hard capsule with a white cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 0.1” in black).</p>
                <p class="mg-025">Talzenna 0.25 mg is supplied as opaque, approximately 14 mm x
                  5 mm hard capsule with an ivory cap (printed with “Pfizer” in black) and a
                  white body (printed with “TLZ 0.25” in black).</p>
                <p class="mg-1">Talzenna 1 mg is supplied as opaque, approximately 14 mm x 5
                  mm hard capsule with a light red cap (printed with “Pfizer” in black) and a white
                  body (printed with “TLZ 1” in black).</p>
                <p class="mg-01">Talzenna 0.1 mg is available in plastic bottles of 30 hard capsules.</p>
                <p class="mg-025">Talzenna 0.25 mg is available in perforated unit dose blister
                  packs of 30, or 60, or 90 hard capsules and in plastic bottles of 30 hard
                  capsules.</p>
                <p class="mg-1">Talzenna 1 mg is available in perforated unit dose blister packs of
                  30 hard capsules and in plastic bottles of 30 hard capsules.</p>
                <p>Not all pack sizes may be marketed.</p>
              </div>
            </text>
          </section>
          <section>
            <title value="Marketing Authorization Holder and Manufacturer" />
            <code>
              <coding>
                <system value="https://www.mhra.gov.uk/" />
                <code value="200000029917" />
              </coding>
              <text value="Marketing Authorization Holder and Manufacturer" />
            </code>
            <text>
              <status value="generated" />
              <div xmlns="http://www.w3.org/1999/xhtml">
                <p>Pfizer Limited</p>
                <p>Ramsgate Road</p>
                <p>Sandwich</p>
                <p>Kent</p>
                <p>CT13 9NJ</p>
                <p>United Kingdom</p>
                <p>
                  <b>Manufacturer</b>
                </p>
                <p>Excella GmbH &amp; Co. KG</p>
                <p>Nürnberger Strasse 12</p>
                <p>90537 Feucht</p>
                <p>Germany</p>
                <p>For any information about this medicine, please contact:</p>
                <p>Medical Information, Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey,
                  KT20 7NS.</p>
                <p>Telephone 01304 616161</p>
                <p>
                  <b>This leaflet was last revised in 03/2024</b>
                </p>
              </div>
            </text>
          </section>
        </section>
      </Composition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="Ingredient/talazoparib01mg" />
    <resource>
      <Ingredient>
        <id value="talazoparib01mg" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi" />
        </meta>
        <identifier>
          <use value="official" />
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta" />
          <value value="9QHX048FRV" />
        </identifier>
        <status value="active" />
        <for>
          <reference value="ManufacturedItemDefinition/mid01mg" />
        </for>
        <role>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi" />
            <code value="100000072072" />
            <display value="Active" />
          </coding>
        </role>
        <allergenicIndicator value="false" />
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta" />
                <code value="9QHX048FRV" />
                <display value="TALAZOPARIB" />
              </coding>
            </concept>
          </code>
          <strength>
            <presentationQuantity>
              <value value="0.1" />
              <unit value="mg" />
            </presentationQuantity>
            <basis>
              <coding>
                <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                <code value="ACTIB" />
              </coding>
              <text value="active ingredient - basis of strength" />
            </basis>
          </strength>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="Ingredient/ingredientsmcc" />
    <resource>
      <Ingredient>
        <id value="ingredientsmcc" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Ingredient-uv-epi" />
        </meta>
        <identifier>
          <use value="official" />
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta" />
          <value value="B357P1G1IF" />
        </identifier>
        <status value="active" />
        <for>
          <reference value="ManufacturedItemDefinition/mid01mg" />
        </for>
        <for>
          <reference value="ManufacturedItemDefinition/mid1mg" />
        </for>
        <for>
          <reference value="ManufacturedItemDefinition/mid025mg" />
        </for>
        <role>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi" />
            <code value="100000072082" />
            <display value="Excipient" />
          </coding>
        </role>
        <allergenicIndicator value="false" />
        <substance>
          <code>
            <concept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta" />
                <code value="B357P1G1IF" />
                <display value="silicified microcrystalline cellulose (microcrystalline cellulose and silicone dioxide)" />
              </coding>
            </concept>
          </code>
        </substance>
      </Ingredient>
    </resource>
  </entry>
  <entry>
    <fullUrl value="SubstanceDefinition/substancetalazoparib" />
    <resource>
      <SubstanceDefinition>
        <id value="substancetalazoparib" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi" />
        </meta>
        <identifier>
          <use value="official" />
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/" />
          <value value="9QHX048FRV" />
        </identifier>
        <version value="1" />
        <status>
          <coding>
            <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/" />
            <code value="1" />
            <display value="Validated (UNII)" />
          </coding>
        </status>
        <molecularWeight>
          <type>
            <text value="exact" />
          </type>
          <amount>
            <value value="380.35" />
          </amount>
        </molecularWeight>
        <structure>
          <molecularFormula value="C19H14F2N6O" />
        </structure>
        <name>
          <name
            value="(8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one" />
          <type>
            <coding>
              <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/" />
              <code value="x" />
              <display value="Chemical Name" />
            </coding>
          </type>
        </name>
      </SubstanceDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="ManufacturedItemDefinition/mid01mg" />
    <resource>
      <ManufacturedItemDefinition>
        <id value="mid01mg" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ManufacturedItemDefinition-uv-epi" />
        </meta>
        <identifier>
          <use value="official" />
          <system value="https://www.mhra.gov.uk/" />
          <value value="99b900c6-4776-4cde-8125-4f6de8e98b98" />
        </identifier>
        <status value="active" />
        <manufacturedDoseForm>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi/" />
            <code value="100000073375" />
            <display value="Capsule, hard" />
          </coding>
        </manufacturedDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi" />
            <code value="200000002113" />
            <display value="Capsule" />
          </coding>
        </unitOfPresentation>
        <manufacturer>
          <reference value="Organization/orgexcellagmbh" />
        </manufacturer>
      </ManufacturedItemDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="AdministrableProductDefinition/ap01mg" />
    <resource>
      <AdministrableProductDefinition>
        <id value="ap01mg" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/AdministrableProductDefinition-uv-epi" />
        </meta>
        <identifier>
          <system value="https://www.who-umc.org/phpid" />
          <value value="identifier" />
        </identifier>
        <status value="active" />
        <formOf>
          <reference value="MedicinalProductDefinition/mp01mg" />
        </formOf>
        <administrableDoseForm>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi" />
            <code value="100000073375" />
            <display value="Capsule, hard" />
          </coding>
        </administrableDoseForm>
        <unitOfPresentation>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi" />
            <code value="200000002113" />
            <display value="Capsule" />
          </coding>
        </unitOfPresentation>
        <producedFrom>
          <reference value="ManufacturedItemDefinition/mid01mg" />
        </producedFrom>
        <routeOfAdministration>
          <code>
            <coding>
              <system value="https://spor.ema.europa.eu/rmswi" />
              <code value="100000073619" />
              <display value="Oral use" />
            </coding>
          </code>
          <targetSpecies>
            <code>
              <coding>
                <system value="https://spor.ema.europa.eu/rmswi" />
                <code value="100000109093" />
                <display value="Human" />
              </coding>
            </code>
          </targetSpecies>
        </routeOfAdministration>
      </AdministrableProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="RegulatedAuthorization/authorization01mg" />
    <resource>
      <RegulatedAuthorization>
        <id value="authorization01mg" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/RegulatedAuthorization-uv-epi" />
        </meta>
        <identifier>
          <use value="official" />
          <system value="https://spor.ema.europa.eu/pmswi" />
          <value value="6ae5b5d9-7372-494c-874b-7dc67d386d2e" />
        </identifier>
        <subject>
          <reference value="MedicinalProductDefinition/mp01mg" />
        </subject>
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi" />
            <code value="220000000061" />
            <display value="Marketing Authorisation" />
          </coding>
        </type>
        <region>
          <coding>
            <system value="urn:iso:std:iso:3166" />
            <code value="GBR" />
            <display value="United Kingdom" />
          </coding>
        </region>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status" />
            <code value="active" />
            <display value="Active" />
          </coding>
        </status>
        <statusDate value="2024-04-11T00:00:00Z" />
        <holder>
          <reference value="Organization/orgpfizerukltd" />
        </holder>
      </RegulatedAuthorization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="Organization/orgpfizerukltd" />
    <resource>
      <Organization>
        <id value="orgpfizerukltd" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi" />
        </meta>
        <identifier>
          <use value="official" />
          <system value="https://spor.ema.europa.eu/omswi" />
          <value value="ORG-100000101" />
        </identifier>
        <active value="true" />
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi" />
            <code value="220000000034" />
            <display value="Marketing authorisation holder" />
          </coding>
          <text value="Marketing authorisation holder" />
        </type>
        <name value="Pfizer Limited" />
        <contact>
          <address>
            <use value="work" />
            <type value="physical" />
            <text value="Pfizer Limited Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom" />
            <line value="Ramsgate Road" />
            <city value="Sandwich" />
            <country value="UK" />
          </address>
        </contact>
      </Organization>
    </resource>
  </entry>
  <entry>
    <fullUrl value="PackagedProductDefinition/ppd01mgbottle30" />
    <resource>
      <PackagedProductDefinition>
        <id value="ppd01mgbottle30" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/PackagedProductDefinition-uv-epi" />
        </meta>
        <identifier>
          <use value="official" />
          <system value="https://spor.ema.europa.eu/pmswi" />
          <value value="2f8c49a7-e592-43ae-b802-55557bd20470" />
        </identifier>
        <name value="Talzenna 0.1 mg plastic bottle of 30 hard capsules" />
        <type>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi" />
            <code value="100000155527" />
            <display value="Chemical Medicinal Product" />
          </coding>
        </type>
        <packageFor>
          <reference value="MedicinalProductDefinition/mp01mg" />
        </packageFor>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status" />
            <code value="active" />
            <display value="Active" />
          </coding>
        </status>
        <statusDate value="2024-04-11T00:00:00Z" />
        <containedItemQuantity>
          <value value="0.1" />
          <system value="http://unitsofmeasure.org" />
          <code value="mg" />
        </containedItemQuantity>
        <manufacturer>
          <reference value="Organization/orgexcellagmbh" />
        </manufacturer>
        <packaging>
          <identifier>
            <system value="https://spor.ema.europa.eu/pmswi" />
            <value value="5913fadd-6172-4282-ad02-19ab9d063b66" />
          </identifier>
          <type>
            <coding>
              <system value="https://spor.ema.europa.eu/rmswi" />
              <code value="100000073497" />
              <display value="Bottle" />
            </coding>
          </type>
          <quantity value="30" />
          <material>
            <coding>
              <system value="https://spor.ema.europa.eu/rmswi" />
              <code value="200000003222" />
              <display value="PolyVinyl Chloride" />
            </coding>
          </material>
        </packaging>
      </PackagedProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="MedicinalProductDefinition/mp01mg" />
    <resource>
      <MedicinalProductDefinition>
        <id value="mp01mg" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi" />
        </meta>
        <identifier>
          <system value="https://www.mhra.gov.uk/" />
          <value value="33e34b03-d69c-4ed6-af46-7a33d30189a1" />
        </identifier>
        <type>
          <coding>
            <system value="http://hl7.org/fhir/medicinal-product-type" />
            <code value="MedicinalProduct" />
            <display value="Medicinal Product" />
          </coding>
        </type>
        <domain>
          <coding>
            <system value="http://hl7.org/fhir/medicinal-product-domain" />
            <code value="Human" />
            <display value="Human use" />
          </coding>
        </domain>
        <status>
          <coding>
            <system value="http://hl7.org/fhir/publication-status" />
            <code value="active" />
            <display value="active" />
          </coding>
        </status>
        <legalStatusOfSupply>
          <coding>
            <system value="https://spor.ema.europa.eu/rmswi" />
            <code value="100000072084" />
            <display value="Medicinal product subject to medical prescription" />
          </coding>
        </legalStatusOfSupply>
        <name>
          <productName value="Talzenna® (talazoparib) 0.1 mg hard capsules" />
          <type>
            <coding>
              <system value="https://spor.ema.europa.eu/lists/220000000000" />
              <code value="220000000001" />
            </coding>
            <text value="Full name" />
          </type>
          <part>
            <part value="Talzenna" />
            <type>
              <coding>
                <system value="https://spor.ema.europa.eu/lists/220000000000" />
                <code value="220000000002" />
              </coding>
              <text value="Invented name part" />
            </type>
          </part>
          <part>
            <part value="talazoparib" />
            <type>
              <coding>
                <system value="https://spor.ema.europa.eu/lists/220000000000" />
                <code value="220000000003" />
              </coding>
              <text value="Scientific name part" />
            </type>
          </part>
          <part>
            <part value="0.1 mg" />
            <type>
              <coding>
                <system value="https://spor.ema.europa.eu/lists/220000000000" />
                <code value="220000000004" />
              </coding>
              <text value="Strength part" />
            </type>
          </part>
          <part>
            <part value="Capsule, hard" />
            <type>
              <coding>
                <system value="https://spor.ema.europa.eu/lists/220000000000" />
                <code value="220000000005" />
              </coding>
              <text value="Pharmaceutical dose form part" />
            </type>
          </part>
          <usage>
            <country>
              <coding>
                <system value="urn:iso:std:iso:3166" />
                <code value="GBR" />
                <display value="United Kingdom" />
              </coding>
            </country>
            <jurisdiction>
              <coding>
                <system value="urn:iso:std:iso:3166" />
                <code value="GBR" />
                <display value="United Kingdom" />
              </coding>
            </jurisdiction>
            <language>
              <coding>
                <system value="urn:ietf:bcp:47" />
                <code value="en" />
                <display value="English" />
              </coding>
            </language>
          </usage>
        </name>
      </MedicinalProductDefinition>
    </resource>
  </entry>
  <entry>
    <fullUrl value="ClinicalUseDefinition/interactionAmiodarone" />
    <resource>
      <ClinicalUseDefinition>
        <id value="36fdf79a-1b9c-11ee-be56-0242ac120002" />
        <meta>
          <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi" />
        </meta>

        <identifier>
          <use value="official" />
          <system value="https://gsrs.ncats.nih.gov/ginas/app/beta" />
          <value value="N3RQ532IUT" />
        </identifier>
        <type value="interaction" />
        <subject>
          <reference value="MedicinalProductDefinition/mp01mg" />
        </subject>
        <subject>
          <reference value="MedicinalProductDefinition/mp025mg" />
        </subject>
        <subject>
          <reference value="MedicinalProductDefinition/mp1mg" />
        </subject>
        <interaction>
          <interactant>
            <itemCodeableConcept>
              <coding>
                <system value="https://gsrs.ncats.nih.gov/ginas/app/beta" />
                <code value="N3RQ532IUT" />
                <display value="Amiodarone" />
              </coding>
            </itemCodeableConcept>
          </interactant>
        </interaction>
      </ClinicalUseDefinition>
    </resource>
  </entry>
</Bundle>
